WHSC1 promotes oncogenesis through regulation of NIMA-related kinase-7 in squamous cell carcinoma of the head and neck

Molecular Cancer Research

Volumn 13, Issue 2, 2015, Pages 293-304

  Saloura, Vassiliki ^a   Cho, Hyun Soo ^a,b   Kiyotani, Kazuma ^a   Alachkar, Houda ^a   Zuo, Zhixiang ^a   Nakakido, Makoto ^a   Tsunoda, Tatsuhiko ^c   Seiwert, Tanguy ^a   Lingen, Mark ^a   Licht, Jonathan ^d   Nakamura, Yusuke ^a   Hamamoto, Ryuji ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^c RIKEN Center for Integrative Medical Sciences   (Japan)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE H3; HISTONE METHYLTRANSFERASE; UNCLASSIFIED DRUG; WOLF HIRSCHHORN SYNDROME CANDIDATE 1; HISTONE; HISTONE LYSINE METHYLTRANSFERASE; NEK7 PROTEIN, HUMAN; NIMA RELATED KINASE; PROTEIN SERINE THREONINE KINASE; REPRESSOR PROTEIN; WHSC1 PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; FEMALE; GENE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HISTONE METHYLATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NIMA RELATED KINASE 7 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; GENE SILENCING; GENETICS; HEAD AND NECK TUMOR; METABOLISM; METHYLATION; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; GENE KNOCKDOWN TECHNIQUES; HEAD AND NECK NEOPLASMS; HISTONE-LYSINE N-METHYLTRANSFERASE; HISTONES; HUMANS; METHYLATION; NIMA-RELATED KINASES; PROTEIN-SERINE-THREONINE KINASES; REPRESSOR PROTEINS;

EID: 84923876890     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-14-0292-T     Document Type: Article

References (55)

1. Cho HS, Hayami S, ToyokawaG, Maejima K, Yamane Y, Suzuki T, et al. RB1 methylation by SMYD2 enhances cell cycle progression through an increase of RB1 phosphorylation. Neoplasia 2012;14:476-86.
2. Cho HS, Suzuki T, Dohmae N, Hayami S, Unoki M, Yoshimatsu M, et al. Demethylation of RB regulator MYPT1 by histone demethylase LSD1 promotes cell cycle progression in cancer cells. Cancer Res 2011;71:1-6.
3. Hayami S, Yoshimatsu M, Veerakumarasivam A, Unoki M, Iwai Y, Tsunoda T, et al. Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway. Mol Cancer 2010;9:59.
4. Ezponda T, Popovic R, Shah MY, Martinez-Garcia E, Zheng Y, Min DJ, et al. The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer. Oncogene 2013;32:2882-90.
5. Mohammad HP, Baylin SB. Linking cell signaling and the epigenetic machinery. Nat Biotech 2010;28:1033-8.
6. Baylin SB. Resistance, epigenetics and the cancer ecosystem. Nat Med 2011;17:288-9.
7. Tomasi TB, Magner WJ, Khan AN. Epigenetic regulation of immune escape genes in cancer. Cancer Immunol Immunoth 2006;55:1159-84.
8. Richon VM, Johnston D, Sneeringer CJ, Jin L, Majer CR, Elliston K, et al. Chemogenetic analysis of human protein methyltransferases. Chem Biol Drug Des 2011;78:199-210.
9. Cloos PA, Christensen J, Agger K, Helin K. Erasing themethyl mark: histone demethylases at the center of cellular differentiation and disease. Genes Dev 2008;22:1115-40.
10. Copeland RA, Solomon ME, Richon VM. Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov 2009;8: 724-32.
11. Kooistra SM, Helin K. Molecular mechanisms and potential functions of histone demethylases. Nat Rev Mol Cell Biol 2012;13:297-311.
12. Volkel P, Angrand PO. The control of histone lysine methylation in epigenetic regulation. Biochimie 2007;89:1-20.
13. Douglas J, Coleman K, Tatton-Brown K, Hughes HE, Temple IK, Cole TR, et al. Evaluation of NSD2 and NSD3 in overgrowth syndromes. Eur J Hum Genet 2005;13:150-3.
14. Toyokawa G, Cho HS, Masuda K, Yamane Y, Yoshimatsu M, Hayami S, et al. Histone lysine methyltransferase wolf-hirschhorn syndrome candidate 1 is involved in human carcinogenesis through regulation of the Wnt pathway. Neoplasia 2011;13:887-98.
15. Hudlebusch HR, Santoni-Rugiu E, Simon R, Ralfkiaer E, Rossing HH, Johansen JV, et al. The histone methyltransferase and putative oncoprotein MMSET is overexpressed in a large variety of human tumors. Clin Cancer Res 2011;17:2919-33.
16. Stec I, Wright TJ, van Ommen GJ, de Boer PA, van Haeringen A, Moorman AF, et al. WHSC1, a 90 kb SET domain-containing gene, expressed in early development and homologous to a Drosophila dysmorphy gene maps in the Wolf-Hirschhorn syndrome critical region and is fused to IgH in t(4;14) multiple myeloma. Hum Mol Genet 1998;7:1071-82.
17. Lauring J, Abukhdeir AM, Konishi H, Garay JP, Gustin JP, Wang Q, et al. The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity. Blood 2008;111: 856-64.
18. Martinez-Garcia E, Popovic R, Min DJ, Sweet SM, Thomas PM, Zamdborg L, et al. The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood 2011;117:211-20.
19. Kuo AJ, Cheung P, Chen K, Zee BM, Kioi M, Lauring J, et al. NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming. Mol Cell 2011;44:609-20.
20. Pei H, Zhang L, Luo K, Qin Y, Chesi M, Fei F, et al. MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites. Nature 2011;470:124-8.
21. Worsham MJ, Stephen JK, Chen KM, Havard S, Shah V, Gardner G, et al. Delineating an epigenetic continuum in head and neck cancer. Cancer Lett 2014;342:178-84.
22. Lingen MW, Pinto A, Mendes RA, Franchini R, Czerninski R, Tilakaratne WM, et al. Genetics/epigenetics of oral premalignancy: current status and future research. Oral Dis 2011;17(Suppl 1):7-22.
23. Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K, et al. The cancer genome atlas pan-cancer analysis project. Nat Genet 2013;45:1113-20.
24. Hayami S, Kelly JD, ChoHS, YoshimatsuM,UnokiM, Tsunoda T, et al. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int J Cancer 2011;128: 574-86.
25. Yoshimatsu M, ToyokawaG, Hayami S, UnokiM, Tsunoda T, Field HI, et al. Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers. Int J Cancer 2011;128: 562-73.
26. Hamamoto R, Furukawa Y, Morita M, Iimura Y, Silva FP, LiM, et al. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol 2004;6:731-40.
27. Hamamoto R, Silva FP, Tsuge M, Nishidate T, Katagiri T, Nakamura Y, et al. Enhanced SMYD3 expression is essential for the growth of breast cancer cells. Cancer Sci 2006;97:113-8.
28. Cho HS, Kelly JD, Hayami S, Toyokawa G, Takawa M, Yoshimatsu M, et al. Enhanced expression of EHMT2 is involved in the proliferation of cancer cells through negative regulation of SIAH1. Neoplasia 2011;13: 676-84.
29. Toyokawa G, Cho HS, Iwai Y, Yoshimatsu M, Takawa M, Hayami S, et al. The histone demethylase JMJD2B plays an essential role in human carcinogenesis through positive regulation of cyclin-dependent kinase 6. Cancer Prev Res 2011;4:2051-61.
30. Takawa M, Cho HS, Hayami S, Toyokawa G, Kogure M, Yamane Y, et al. Histone lysine methyltransferase SETD8 promotes carcinogenesis by deregulating PCNA expression. Cancer Res 2012;72:3217-27.
31. Kogure M, Takawa M, Cho HS, Toyokawa G, Hayashi K, Tsunoda T, et al. Deregulation of the histone demethylase JMJD2A is involved in human carcinogenesis through regulation of the G/S transition. Cancer Lett 2013; 336:76-84.
32. Cho HS, Toyokawa G, Daigo Y, Hayami S, Masuda K, Ikawa N, et al. The JmjC domain-containing histone demethylase KDM3A is a positive regulator of the G1/S transition in cancer cells via transcriptional regulation of the HOXA1 gene. Int J Cancer 2012;131:E179-89.
33. Kang D, Cho HS, Toyokawa G, Kogure M, Yamane Y, Iwai Y, et al. The histone methyltransferase Wolf-Hirschhorn syndrome candidate 1-like 1 (WHSC1L1) is involved in human carcinogenesis. Genes Chromosomes Cancer 2013;52:126-39.
34. Kogure M, Takawa M, Saloura V, Sone K, Piao L, Ueda K, et al. The oncogenic polycomb histone methyltransferase EZH2 methylates lysine 120 on histone H2B and competes ubiquitination. Neoplasia 2013;15:1251-61.
35. O'Regan L, Fry AM. The Nek6 and Nek7 protein kinases are required for robust mitotic spindle formation and cytokinesis. Mol Cell Biol 2009;29:3975-90.
36. Fry AM, O'Regan L, Sabir SR, Bayliss R. Cell cycle regulation by the NEK family of protein kinases. J Cell Sci 2012;125:4423-33.
37. Curtin JF, Cotter TG. JNK regulates HIPK3 expression and promotes resistance to Fas-mediated apoptosis in DU 145 prostate carcinoma cells. J Biol Chem 2004;279:17090-100.
38. Boivin A, Hanot M, Malesys C, Maalouf M, Rousson R, Rodriguez-Lafrasse C, et al. Transient alteration of cellular redox buffering before irradiation triggers apoptosis in head and neck carcinoma stem and nonstem cells. PLoS ONE 2011;6:e14558.
39. Moniz L, Dutt P,Haider N, Stambolic V. Nek family of kinases in cell cycle, checkpoint control and cancer. Cell Div 2011;6:18.
40. Patil M, Pabla N, Ding HF, Dong Z. Nek1 interacts with Ku80 to assist chromatin loading of replication factors and S-phase progression. Cell Cycle 2013;12:2608-16.
41. Helin K, Dhanak D. Chromatin proteins and modifications as drug targets. Nature 2013;502:480-8.
42. Wagner T, Jung M.New lysine methyltransferase drug targets in cancer.Nat Biotech 2012;30:622-3.
43. Wee S, Dhanak D, Li H, Armstrong SA, Copeland RA, Sims R, et al. Targeting epigenetic regulators for cancer therapy. Ann N Y Acad Sci 2014;1309:30-6.
44. Zagni C, Chiacchio U, Rescifina A. Histone methyltransferase inhibitors: novel epigenetic agents for cancer treatment. Curr Med Chem 2013;20: 167-85.
45. McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012;492:108-12.
46. Qi W, Chan H, Teng L, Li L, Chuai S, Zhang R, et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci U S A 2012;109:21360-5.
47. Nimura K, Ura K, Shiratori H, Ikawa M, Okabe M, Schwartz RJ, et al. A histone H3 lysine 36 trimethyltransferase links Nkx2-5 to Wolf-Hirschhorn syndrome. Nature 2009;460:287-91.
48. Kim S, Kim S, Rhee K. NEK7 is essential for centriole duplication and centrosomal accumulation of pericentriolar material proteins in interphase cells. J Cell Sci 2011;124:3760-70.
49. O'Regan L, Blot J, Fry AM. Mitotic regulation by NIMA-related kinases. Cell Div 2007;2:25.
50. Bertran MT, Sdelci S, Regue L, Avruch J, Caelles C, Roig J. Nek9 is a Plk1-activated kinase that controls early centrosome separation through Nek6/7 and Eg5. EMBO J 2011;30:2634-47.
51. Wang R, Song Y, Xu X, Wu Q, Liu C. The expression of Nek7, FoxM1, and Plk1 in gallbladder cancer and their relationships to clinicopathologic features and survival. Clin Transl Oncol 2013;15:626-32.
52. de Carcer G, Perez de Castro I, Malumbres M. Targeting cell cycle kinases for cancer therapy. Curr Med Chem 2007;14:969-85.
53. Malumbres M, Barbacid M. Cell cycle kinases in cancer. Curr Opin Genet Dev 2007;17:60-5.
54. Kokuryo T, Senga T, Yokoyama Y, Nagino M, Nimura Y, Hamaguchi M. Nek2 as an effective target for inhibition of tumorigenic growth and peritoneal dissemination of cholangiocarcinoma. Cancer Res 2007;67: 9637-42.
55. Westwood I, Cheary DM, Baxter JE, RichardsMW,van Montfort RL, Fry AM, et al. Insights into the conformational variability and regulation of human Nek2 kinase. J Mol Biol 2009;386:476-85.